Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT
Comparative Effectiveness of Nadroparin Versus Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients With Refractory Asymptomatic Portal Vein Thrombosis:a Multicenter, Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jie CHEN, MD
- Phone Number: 8613764633539
- Email: chen.jie5@zs-hospital.sh.cn
Study Contact Backup
- Name: Lili Liu, MD
- Phone Number: 862164041990-612632
- Email: liu.lili@zs-hospital.sh.cn
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with liver cirrhosis
- Diagnosis of portal vein thrombosis through computed tomographic venography with a thrombus diameter exceeding 30% of the vessel diameter.
- Consent to participate in the clinical trial and the signing of an informed consent form.
Exclusion Criteria:
- Presence of acute symptoms such as fever, abdominal pain or bleeding, or of cavernous transformation
- Patients with Child-Pugh C.
- Pregnant or lactating women.
- With a history of liver cancer or other malignancy.
- Severe heart, lung diseases, or significant renal dysfunction.
- Allergies to anticoagulant medications, uncontrolled hypertension, history of cerebral hemorrhage, discovery of gastrointestinal ulcers, ulcerative colitis, subacute bacterial endocarditis, or other contraindications to anticoagulant drugs.
- On concomitant therapy of immunosuppressive drugs.
- With coagulation disorders other than liver disease.
- With active variceal bleeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TIPS group
The cirrhotic patients with persistent PVT despite 6 months of anticoagulation therapy will receive transjugular-intrahepatic-portosystemic shunt.
|
Using the transjugular approach, TIPS was created under local anesthesia.
The first branch of the left or right portal vein (PV) was punctured by RUPS-100 set guided by digital subtraction angiography.
After successful access into PV, direct portography was performed and all visible varices and/or concurrent spontaneous portosystemic shunts (SPSS) were embolized with coils and n-butyl cyanoacrylate.
A polytetrafluoroethylene-covered stent (Viatorr Endoprosthesis, GORE and Associates, Flagstaff, Arizona, USA) with a diameter of 8 mm was implanted and fully dilated.
|
|
Active Comparator: Nadroparin group
The cirrhotic patients with persistent PVT despite 6 months of anticoagulation therapy will continue with the nadroparin therapy
|
Nadroparin calcium will be subcutaneously injected with the dose of 85IU/kg q12h
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
complete recanalization rate of PVT
Time Frame: 6 months
|
Enhanced abdominal CT scan will be performed to assess the recanalization of PVT.
The primary outcome is the complete recanalization.
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
partial recanalization rate of PVT
Time Frame: 6 months
|
Enhanced abdominal CT scan will be performed to assess the recanalization of PVT.
Partial recanalization is defined as decrease of PVT more than 50%.
|
6 months
|
|
Bleeding rate
Time Frame: 6 months
|
Bleeding events related to anticoagulant therapy.
Bleeding events will be further classified into major and minor according to the established criteria outlined by the International Society of Thrombosis and Haemostasis
|
6 months
|
|
Mortality
Time Frame: 6 months
|
Survival analysis
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jian Wang, MD, Shanghai Zhongshan Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Tipharosis
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.